Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

University of Manitoba

$36,000.00

Relaxin and its receptor RXFP1 in cell motility

FY 2013-14

Summary
My research program has established relaxin (RLN2) and INSL3 and their cognate G protein coupled receptors, RXFP1 and RXFP2, as novel mediators of cell migration and extracellular matrix (ECM) degradation. These peptides induce the expression of powerful cathepsins, matrix-metalloproteinases MMP14, MMP2, and the MMP inhibitor TIMP2, and the Ca2+-binding protein S100A4 to facilitate ECM penetration and enhanced motility of thyroid cells. My recent discovery that RLN2 remodels the protein composition at the leading migrating edge of the protruding cell membrane, called pseudopodia, has opened new and exciting avenues in relaxin research. Proteins enriched by relaxin at the leading migrating edge can now be mapped to appreciate the impact of the RLN2-RXFP1 system in thyroid cells. Through targets like S100A4, RLN2 can activate the Wnt pathway to affect thyroid cell motility and I will explore the cross-talk between RXFP1 and Wnt signaling. Exposure of migrating cells to a changing micro-environment makes cells vulnerable to forms of programmed cell death (PCD). Employing novel 3D-nanoresolution imaging and other sophisticated tools available to me, I will explore if the anti-apoptotic actions of RXFP1 signaling we observed in-vivo can protect migrating cells against PCD. The successfully established new cre-lox transgenic (tg) mouse strain for the controlled tissue-specific activation of a constitutively active mutant RXFP1 will allow me now to generate double tg mice for thyroid-specific activation of RXFP1. These mice are then challenged by the induction of a hypothyroid and hyperthyroid stress and the effects of consistent RXFP1 signaling on thyroid endocrine system are evaluated. My unique program contributes new and unique data on the role of RLN2-RXFP1 in the thyroid. My previous data showed a significant functional overlap between the RLN2-RXFP1 and INSL3-RXFP2 in the thyroid. Thus, this proposal is likely to generate new and important data for both relaxin-like ligand-receptor systems in the thyroid.
Program
Discovery Grants Program - Individual
Location
Manitoba, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
342187-2011
Name nom
Klonisch, Thomas
Department département
Human Anatomy & Cell Science
Organization id
19
Institution établissement
University of Manitoba
Province en
Manitoba
Province fr
Manitoba
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2011
Award amount
36000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5108
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Cell movement
Research subject fr
Mouvements cellulaires
Partie
3
Nb partie
5
Application title
Relaxin and its receptor RXFP1 in cell motility
Keyword
NSERC
Application summary
My research program has established relaxin (RLN2) and INSL3 and their cognate G protein coupled receptors, RXFP1 and RXFP2, as novel mediators of cell migration and extracellular matrix (ECM) degradation. These peptides induce the expression of powerful cathepsins, matrix-metalloproteinases MMP14, MMP2, and the MMP inhibitor TIMP2, and the Ca2+-binding protein S100A4 to facilitate ECM penetration and enhanced motility of thyroid cells. My recent discovery that RLN2 remodels the protein composition at the leading migrating edge of the protruding cell membrane, called pseudopodia, has opened new and exciting avenues in relaxin research. Proteins enriched by relaxin at the leading migrating edge can now be mapped to appreciate the impact of the RLN2-RXFP1 system in thyroid cells. Through targets like S100A4, RLN2 can activate the Wnt pathway to affect thyroid cell motility and I will explore the cross-talk between RXFP1 and Wnt signaling. Exposure of migrating cells to a changing micro-environment makes cells vulnerable to forms of programmed cell death (PCD). Employing novel 3D-nanoresolution imaging and other sophisticated tools available to me, I will explore if the anti-apoptotic actions of RXFP1 signaling we observed in-vivo can protect migrating cells against PCD. The successfully established new cre-lox transgenic (tg) mouse strain for the controlled tissue-specific activation of a constitutively active mutant RXFP1 will allow me now to generate double tg mice for thyroid-specific activation of RXFP1. These mice are then challenged by the induction of a hypothyroid and hyperthyroid stress and the effects of consistent RXFP1 signaling on thyroid endocrine system are evaluated. My unique program contributes new and unique data on the role of RLN2-RXFP1 in the thyroid. My previous data showed a significant functional overlap between the RLN2-RXFP1 and INSL3-RXFP2 in the thyroid. Thus, this proposal is likely to generate new and important data for both relaxin-like ligand-receptor systems in the thyroid.
University of Manitoba - $36,000 Grant (2013-14) | Canada Spends